Taiwan-developed drug to be tested on severe COVID-19 cases in U.S.

A drug candidate developed by a Taiwanese company for the treatment of COVID-19 will be administered to seriously ill patients in its Phase II clinical trials in the United States, pending authorization by the relevant authorities, according to the developer Golden Biotechnology Corp.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)